Program
CKD-383
A development code. Also written as “CKD-383 0.5/10/1000mg”, “CKD-383 0.5/25/1000mg” and “CKD-383 0.25/12.5/1000mg”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by Chong Kun Dang Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | 101 open or running | phase 1since Mar 11, 2021 | Mar 11, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2021First study: phase 1 study in Type2 Diabetes MellitusFirst studyNCT04810676 · 27 enrolled · Korea, Republic of
- Apr 5, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05816759 · 32 enrolled · Korea, Republic of
- Jun 1, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05897216 · 30 enrolled · Korea, Republic of
- Jun 13, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06483243 · 45 enrolled · Korea, Republic of
- Jul 1, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06492655 · 28 planned
- Nov 17, 20242 phase 1 studies in Diabetes Mellitus, Type 2NCT06695598, NCT06695572
- Dec 14, 20253 phase 1 studies in Diabetes Mellitus, Type 2NCT07304726, NCT07304700, NCT07304687
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07304726Diabetes Mellitus, Type 2 · South Korea | 1 | Completed | Nov 9, 2025 | 30 |
| NCT07304700Diabetes Mellitus, Type 2 · South Korea | 1 | Completed | Nov 7, 2025 | 30 |
| NCT07304687Diabetes Mellitus, Type 2 · South Korea | 1 | Completed | Nov 3, 2025 | 31 |
| NCT06695598Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Dec 8, 2024 | 30 |
| NCT06695572Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Dec 7, 2024 | 30 |
| NCT06492655Diabetes Mellitus, Type 2 | 1 | Not yet recruiting | Aug 1, 2024 | 28 |
| NCT06483243Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Apr 29, 2024 | 45 |
| NCT05897216Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Jul 23, 2023 | 30 |
| NCT05816759Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Jun 4, 2023 | 32 |
| NCT04810676Type2 Diabetes Mellitus · Korea, Republic of | 1 | Completed | May 20, 2021 | 27 |
How it is read
Names in the registry
- “CKD-383”, 5 entries
- “CKD-383 0.5/10/1000mg”, 1 entry
- “CKD-383 0.5/25/1000mg”, 1 entry
- “CKD-383 0.25/12.5/1000mg”, 1 entry
- “CKD-383(Fed)”, 1 entry
Codes read as this program: CKD383.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 10 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.